EU pharmaceutical reform advances as member states approve Council first-reading positions
EU pharmaceutical legislation has moved closer to completion after member states backed the Council's first-reading positions on the regulation and directive forming the bloc's revised medicines framework.
The texts cover centralised medicine authorisation and EMA oversight as well as a revised Union code for medicinal products for human use.
The step advances the legislative package toward formal Council adoption and subsequent completion of the EU law-making process.
Field | Content |
Alert Type | Industry Update |
Development | EU pharmaceutical legislation reform |
Institution | Council of the European Union |
Policy Area | Medicines regulation; pharmaceutical legislation |
Legislative Instruments | Regulation governing Union procedures for authorisation and supervision of medicinal products and EMA rules; Directive establishing the Union code for medicinal products for human use |
Geography | European Union |
What Happened | Member states advanced the Council's first-reading positions on the regulation and directive forming the revised EU pharmaceutical framework. |
Why It Matters | The package is intended to replace and update major parts of the EU's existing medicines legislation and will affect pharmaceutical regulation across the bloc. |
Supporting Context | Council documents published around the 23 September Coreper meeting include first-reading positions on both the medicinal-products regulation and the new Union medicines code. |
Potential Impact | Once the legislation completes the remaining formal steps, pharmaceutical companies will need to adapt regulatory, development and market-access strategies to the revised framework. |
Key Takeaway | The EU pharmaceutical reform package has moved into its first-reading adoption stage at Council level. |
What to Watch | Formal Council adoption and the remaining institutional steps before the revised pharmaceutical legislation enters into force. |
Primary Source | Council of the European Union |
Relevant Date | 23-24 September 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Comentarios